pk10走势图怎么看性别

Another batch of procurement with volume is about to start!

Release date: 2020-01-14 Views: 0

Source: Medical Representative  

On January 13, the Fujian Medical Insurance Bureau, the Fujian Provincial Health and Health Commission, and the Drug Administration issued the "Notice of Expanding the Scope of Centralized Drug Volume Purchase", which requires large purchase amounts, sufficient competition, mature clinical use, and the same common name. For drugs that have not yet passed the consistency evaluation of quality and efficacy of generic drugs, the provincial medical insurance bureau, the health and health commission, and the drug regulatory bureau jointly organize the experts to select and select the selected drugs into the scope of centralized volume procurement.

Specifically, according to the total amount of generic drugs (excluding reference preparations, FDA-approved generic drugs sold in Europe and the United States) that failed to pass the quality and efficacy consistency evaluation in the same generic name of public medical institutions in Fujian Province last year, 70% of the estimated basic amount of procurement, to ensure that the basic amount is completed within the procurement cycle. In principle, the amount of selected drugs used is not less than the generic generic drugs (excluding reference preparations, FDA-approved generic drugs that are sold in Europe and the United States). 60% of the amount, purchase with quantity and exchange price with quantity.

From the above, it is mainly the generic drugs with large clinical dosages that have not passed the consistency evaluation. The specific ones will be selected and still need to be notified by the official next step.

The following is the original text and official interpretation:

Fujian Medical Security Bureau

Fujian Provincial Health Committee

Fujian Drug Administration

Notice on expanding the scope of centralized drug procurement

Each district and city medical insurance bureau, health and health commission, market supervision bureau, Pingtan comprehensive experimental zone social undertaking bureau, health and health bureau, market supervision bureau, and relevant medical institutions, drug production, distribution (distribution) enterprises:

In accordance with the spirit of the "Opinions of the Fujian Provincial Party Committee of the Communist Party of China and the Fujian Provincial People's Government on Promoting the" Sanming Experience "to Deepen the Reform of the Medical and Health System" (Fujian Fafa [2019] No. 19) The reform of the medical and health system, consolidating the province's comprehensive implementation of the follow-up of the national drug procurement and pilot trials, further improving the centralized drug procurement mechanism and market-led drug price formation mechanism, reducing the burden of drug costs for the masses, and now expanding the drug concentration belt The notice of the scope of the volume purchase is as follows:

I. Expanding the scope of centralized procurement and use of drugs

In accordance with the principles of active and prudent, step-by-step advancement, some medicines with large purchase amounts, sufficient competition, mature clinical use, and generic drugs with the same generic name that have not yet passed the consistency and quality evaluation of generic drugs are provided by the Provincial Medical Insurance Bureau, the Health Commission, The CFDA jointly organized the experts to carry out the selection, included the selected drugs into the scope of centralized procurement, and implemented them in public medical institutions throughout the province, encouraging the participation of the Fujian Army, Armed Police Medical Institutions and other medical institutions.

Second, the implementation of selected drugs with quantity procurement, exchange for quantity

According to the province ’s public medical institutions in the previous year, 70% of the total amount of generic drugs of the same generic name that have not passed the consistency evaluation of quality and efficacy (generic drugs without reference preparations, FDA-certified, and sold in Europe and the United States) are used to estimate the procurement base. In order to ensure that the basic quantity is completed within the procurement cycle, the amount of selected drugs is in principle not less than 60% of the total use of generic drugs of the same generic name (excluding reference preparations, FDA-approved generic drugs and sales in Europe and the United States). Buy with quantity and exchange price with quantity. Explore cross-regional joint development of centralized volume procurement. The pilot procurement cycle will last for one year from the formal implementation of centralized volume procurement.

Third, ensure the procurement and use of selected drugs

The health and medical insurance departments decomposed the basic quantities of selected medicines into various public medical institutions in the province, and organized medical institutions, selected manufacturing enterprises, and distribution companies to sign purchase and sales contracts with quantity. The medical institution shall directly include the selected drugs in the medical institution's drug catalogue, and ensure that the agreed purchase amount is completed within one year. For medical institutions that have not completed the procurement and use of selected drugs, and medical personnel who do not use the selected drugs in accordance with the regulations, refer to Notice (Minzheng Office [2019] No. 31) related provisions.

4. Guaranteeing the Quality and Supply of Selected Drugs

Production and distribution companies should strictly fulfill their purchase and sales contracts to ensure the quality and supply of medicines. For actions such as inability to guarantee quality and unscheduled supply in the course of implementation, measures such as compensation, punishment, withdrawal, alternatives and emergency guarantees shall be adopted. The drug supervision department strengthened the quality supervision of the whole chain of the production, circulation and use of the selected drugs, increased the frequency and coverage of random inspections, and announced the inspection results in time to ensure the safety of drug use by the masses.

V. Improving medical insurance payment settlement

The selected drugs are sold at zero margin, and the selected price is used as the medical insurance payment standard within the medical insurance catalog. In principle, for other unreviewed drugs under the same general name, the medical insurance fund will settle according to the same payment standards. If the price of the drug used by the patient is significantly higher than the price of the selected drug, the medical insurance payment standard shall be adjusted according to the 2-3 year transition period. The drug payment shall be settled uniformly by the medical insurance agency.

Six, strengthen organizational implementation

Relevant departments in various places should attach great importance to strengthen the responsibility, further decompose and refine the work tasks according to the requirements of functions and division of labor, strengthen communication and coordination, improve the working mechanism, and promote the implementation of the work. Strengthen follow-up evaluation, and do a good job of management and supervision throughout the process. Pay attention to publicity and guidance, respond to concerns in a timely manner, and create a good atmosphere for the whole society to support reform.

Fujian Provincial Medical Security Bureau Fujian Provincial Health Committee

Fujian Drug Administration

December 31, 2019

Interpretation of the "Notice on Expanding the Scope of Centralized Drug Purchase"

In accordance with the spirit of the "Opinions of the Fujian Provincial Party Committee of the Communist Party of China and the Fujian Provincial People's Government on Promoting the" Sanming Experience "and Deepening the Reform of the Medical and Health System" (Fujian Fafa [2019] No. 19) The Provincial Health and Health Committee and the Provincial Drug Administration jointly issued and issued the “Notice on Expanding the Scope of Centralized Drug Procurement and Purchasing,” and the main contents are now read as follows:

I. Development background

The state-run pilot program for centralized procurement and use of pharmaceuticals was first launched in Xiamen on March 18. Our province is the first country in China to introduce the "Fujian Province's Implementation Plan for Follow-up of National Organizations' Centralized Drug Purchasing and Use Pilot Work". The results of the selection will be listed on the provincial procurement platform on June 1. Patients will be available on June 3. The selected drugs are used at the selected price, and the medical insurance supporting policy is implemented simultaneously, becoming the first province to follow the provincial government's centralized procurement and use of pharmaceuticals. Since the implementation of the pilot program, our province's follow-up procurement work has been generally stable and has achieved obvious results, forming a good situation in which the masses are satisfied, the hospital is motivated, and the enterprise is rationally treated.

In order to deepen the reform of the province's medical and health system, consolidate the province's comprehensive implementation of the follow-up of the national drug procurement and use pilot results, further improve the centralized drug procurement mechanism and market-led drug price formation mechanism, and reduce the burden of drug costs for the population, according to the " Fujian Provincial Committee of the Communist Party of China and Fujian Provincial People's Government on Promoting the "Sanming Experience" to Deepen the Reform of the Medical and Health System (Minhuifa [2019] No. 19) in the spirit of the provincial medical reform leading group to study and agree to expand the centralized procurement range.

Specific content

(I) Expand the scope of centralized procurement of drugs

Some medicines with large purchase amounts, sufficient competition, mature clinical use, and generic drugs with the same generic name that have not passed the consistency evaluation of quality and efficacy, will be jointly selected by the Provincial Medical Insurance Bureau, the Health and Health Commission, and the Drug Administration to develop a concentrated area. Volume purchase.

(2) Purchasing with quantity and price for quantity

Based on 70% of the total amount of generic drugs that failed to pass the consistency evaluation of quality and efficacy in the same common name of public medical institutions in the province in the previous year, the estimated basic amount of procurement is to ensure that the basic amount is completed within the procurement cycle. Generic generic drugs use 60% of the total amount, purchase with quantity, and exchange price with quantity.

(Three) to ensure the use of procurement

The health and medical insurance departments organize medical institutions, selected manufacturing enterprises, and distribution companies to sign purchase and sales contracts with quantity. The medical institution shall directly include the selected drugs in the medical institution's drug catalogue, and ensure that the agreed purchase amount is completed within one year.

(4) Guarantee quality

Production and distribution companies effectively guarantee the quality and supply of medicines. The drug supervision department strengthened the quality supervision of the whole chain of the production, circulation and use of the selected drugs, increased the frequency and coverage of random inspections, and announced the inspection results in time to ensure the safety of drug use by the masses.

(V) Improving medical insurance payment settlement

The selected drugs are sold at zero margin, and the selected price is used as the medical insurance payment standard within the scope of the medical insurance catalog. In principle, for other unreviewed drugs under the same general name, the medical insurance fund will settle according to the same payment standards. The drug payment shall be settled uniformly by the medical insurance agency.

(6) Strengthen organization and implementation

Relevant departments in various places must attach great importance to the breakdown of detailed work tasks, strengthen communication and coordination, and promote the implementation of the work; second, strengthen tracking and evaluation, and manage and supervise the whole process; third, pay attention to publicity and guidance, respond to concerns in a timely manner, and build a society A good atmosphere to support reform.

latest articles

recommended article

Hunter QR code